Outlier ophthalmologists in the treatment of neovascular age-related macular degeneration with intravitreal therapy

Macular Diseases

Intravitreal faricimab for treatment naïve patients with neovascular age-related macular degeneration: a real-world prospective study

Int J Retina Vitreous

Grimaldi G, Cancian G, Paris A, Clerici M, Volpe G, Menghini M

doi: 10.1186/s40942-024-00586-w

Macular Diseases

Comparative efficacy of intravitreal anti-VEGF therapy for neovascular age-related macular degeneration: A systematic review with network meta-analysis

Acta Ophthalmol

Butler ETS, Arnold-Vangsted A, Schou MG, Anguita R, Bjerager J, Borrelli E, Cehofski LJ, Ferro Desideri L, van Dijk EHC, Faber C, Grauslund J, Hajari JN, Huemer J, Klefter ON, Krogh Nielsen M, Sabaner MC, Schneider M, Subhi Y

doi: 10.1111/aos.17506

Macular Diseases

Cost-minimisation analysis of anti-VEGF therapies in neovascular age-related macular degeneration and diabetic macular oedema in Switzerland

J Med Econ

Ambresin A, Quist SW, Boer M, Maamari S, Barthelmes D

doi: 10.1080/13696998.2025.2536420

Macular Diseases

Incidence and reasons for discontinuation of anti-VEGF treatment in neovascular age-related macular degeneration

Br J Ophthalmol

Borrelli E, Foti C, Ulla L, Porreca A, Introini U, Grassi MO, Viggiano P, Peronetti M, Toscani R, Boscia G, Termite AC, Gennaro C, Marolo P, Boscia F, Bandello F, Reibaldi M

doi: 10.1136/bjo-2024-326152

Macular Diseases

Acceptance of the Disease in Patients Diagnosed with Neovascular Age-Related Macular Degeneration Depending on Visual Parameters-Before and After a Series of Seven Intravitreal Injections

J Clin Med

Nowak M, Cybulska AM, Schneider-Matyka D, Grochans E, Walaszek I, Panczyk M, Nowicki GJ, Rachubińska K

doi: 10.3390/jcm14020447

Macular Diseases

Real-World Experience with Intravitreal Pegcetacoplan for the Treatment of Geographic Atrophy in Age-Related Macular Degeneration

Am J Ophthalmol

Shen M, Berni A, Liu J, Hiya F, Herrera G, El-Mulki OS, Beqiri S, Cheng Y, Kastner J, Trivizki O, Kumar S, Zhang Y, Le VH, O'Brien RC, Nicola MD, Yehoshua Z, Dubovy SR, Wang RK, Gregori G, Rosenfeld PJ

doi: 10.1016/j.ajo.2025.09.006

Macular Diseases

Efficacy and safety of brolucizumab every 6 weeks induction therapy for neovascular age-related macular degeneration

Sci Rep

Honda S, Maruyama-Inoue M, Otsuji T, Kyo A, Kobayashi Y, Yamamoto Y, Gomi F

doi: 10.1038/s41598-025-89638-1

Macular Diseases

One-Year Real-World Outcomes of Intravitreal Faricimab for Previously Treated Neovascular Age-Related Macular Degeneration

Ophthalmol Ther

Cancian G, Paris A, Agliati L, Rizzato A, Clerici M, Volpe G, Menghini M, Grimaldi G

doi: 10.1007/s40123-024-01036-4

Macular Diseases

Real-World 10-Year Outcomes of Anti-VEGF Therapy for Neovascular Age-Related Macular Degeneration: A Meta-Analysis

Clin Exp Ophthalmol

Spooner K, Broadhead G, Fraser-Bell S, Hong T, Wong JG, Chang AA

doi: 10.1111/ceo.14559

Related content

Intravitreal faricimab for treatment naïve patients with neovascular age-related macular degeneration: a real-world prospective study

Comparative efficacy of intravitreal anti-VEGF therapy for neovascular age-related macular degeneration: A systematic review with network meta-analysis

Cost-minimisation analysis of anti-VEGF therapies in neovascular age-related macular degeneration and diabetic macular oedema in Switzerland

Incidence and reasons for discontinuation of anti-VEGF treatment in neovascular age-related macular degeneration

Acceptance of the Disease in Patients Diagnosed with Neovascular Age-Related Macular Degeneration Depending on Visual Parameters-Before and After a Series of Seven Intravitreal Injections

Real-World Experience with Intravitreal Pegcetacoplan for the Treatment of Geographic Atrophy in Age-Related Macular Degeneration

Efficacy and safety of brolucizumab every 6 weeks induction therapy for neovascular age-related macular degeneration

One-Year Real-World Outcomes of Intravitreal Faricimab for Previously Treated Neovascular Age-Related Macular Degeneration

Real-World 10-Year Outcomes of Anti-VEGF Therapy for Neovascular Age-Related Macular Degeneration: A Meta-Analysis